Avanir Pharmaceuticals Inc announces submission of new drug application for AVP-825 for the acute treatment of migraine


Thursday, 30 Jan 2014 09:00am EST 

Avanir Pharmaceuticals Inc:Says that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its Breath Powered investigational drug-device combination product for the acute treatment of migraine. 

Company Quote

16.85
-0.14 -0.82%
19 Dec 2014